Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2016

Electronic Supplementary data for

Copper-mediated arylsulfanylations and arylselanylations of pyrimidine or 7deazapurine nucleosides and nucleotides

Filip Botha^a, Michaela Slavíčková,^a Radek Pohl^a, and Michal Hocek^{ab*}

^{*a*} Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead & IOCB Research Center, Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic

^b Department of Organic Chemistry, Faculty of Science, Charles University in Prague, Hlavova 8, CZ-12843 Prague 2, Czech Republic

E-mail: hocek@uochb.cas.cz

Table of Contents:

1. Experimental part	S2
2. Copies of NMR spectra	S26
3. Copies of MALDI spectra	S67
4. References	S69

Experimental part

Materials and instrumentation

All chemicals were purchased from commercial sources and were used without further purification. Copper powder (spheroidal), 14-25 µm was purchased from Sigma-Aldrich[®]. Dry DMF was used as received from supplier, CHCl₃ was distilled prior column chromatography. PO(OMe)₃ was dried, distilled and POCl₃ distilled using conventional methods prior use. All compounds were fully characterized by NMR spectroscopy and the spectra were recorded on a Bruker Avance-IIIHD 600 (¹H at 600.1 MHz, and ¹³C at 150.9 MHz) or on a Bruker Avance-IIIHD 500 (500.0 MHz for ¹H, 125.7 MHz for ¹³C, 202.3 MHz for ³¹P and 95.4 MHz for ⁷⁷Se) spectrometer. ¹H and ¹³C resonances were assigned using H,H-COSY, H,C-HSQC and H,C-HMBC 2D NMR spectra. The samples were measured in DMSO-d₆ or in D₂O and chemical shifts (δ -scale, in ppm) were referenced to residual solvent signal (DMSO (δ (1 H) = 2.50 ppm, δ (¹³C) = 39.70 ppm) or to 1.4-dioxane as external standard in the case of D₂O solutions (δ (¹H) = 3.75 ppm, δ (¹³C) = 69.30 ppm); ³¹P spectra were referenced to H₃PO₄ as an external standard $(\delta (^{31}P) = 0 \text{ ppm})$ and ⁷⁷Se spetra were referenced to Me₂Se as an external standard ($\delta (^{77}Se) =$ 0 ppm). Coupling constants (J) are given in Hz. The following abbreviations (or a combination of thereof) were used to explain signal multiplicities: s = singlet, d = doublet, t = triplet, q =quartet, m = multiplet, b = broad. The purity of substances and the courses of the reactions were monitored by thin layer chromatography using TLC aluminium sheets with Silica gel 60 F₂₅₄ (Merck) and analysed at 254 and/or 365 nm. Column chromatography was performed using Silica gel Geduram 60 F₂₅₄ (Merck, particle size 0.063–0.200 mm). Reversed-phase highperformance flash chromatography (RP-HPFC) purifications were performed with Biotage SP1 apparatus on KP-C18-HS 25+M and 40+M columns. Semipreparative separations of 2'deoxyribonucleosides 5'-*O*-triphosphates (dNTPs), 2'-deoxyribonucleosides 5'-0monophosphates (dNMPs) or 2'-deoxyribonucleosides (dNs) were performed using HPLC on a column packed with 10 µm C-18 reverse phase [Phenomenex, Luna C18 (2)]. All reverse phase columns were treated/regenerated with sufficient amount of DMSO and aq. EDTA disodium salt solution after each purification of a Cu-mediated reaction mixture. High resolution mass spectra were measured on a LTQ Orbitrap XL (Thermo Fisher Scientific) spectrometer using ESI ionization technique.

General procedure for copper-mediated arylsulfanylations of arylselenylations of nucleosides (dN^I) (Method A):

To a U-shaped microwave vial sealable with a Teflon cap were added **dN**^I (0.255 mmol, 1 equiv.), Cu powder (16.2 mg, 0.255 mmol, 1 equiv.), 2,2'-bipyridyl (9.9 mg, 0.063 mmol, 0.25 equiv.) and corresponding diselenide or disulfide (0.140 mmol, 0.55 equiv.). The vessel was capped and then evacuated and backfilled with Ar three times. DMF (2.1 ml, degassed) was injected via a syringe (liquid dimethyl diselenide was added via a Hamilton syringe at this stage) and the vessel was evacuated and backfilled with Ar and the contents were sonicated. The reaction mixture was heated to 80 °C or 110 °C, vigorously stirred and the consumption of starting nucleoside was carefully monitored by TLC on SiO₂ using CHCl₃/MeOH = 5/1 or 10/1 v/v as an eluent (the colour changes during the reaction to dark red). The reaction was quenched by addition of MeOH (5 ml), the precipitate was filtered off and the filtrate evaporated to dryness *in vacuo*. The solid residue was either loaded on SiO₂ by co-evaporation from CHCl₃/MeOH, and purified by column chromatography (SiO₂, CHCl₃/MeOH = 5/1 or 10/1 v/v) or reverse phase HPFC (C-18, 0 \rightarrow 100% MeOH in water; solid residue was dissolved in approx. 5 ml DMSO/H₂O=1/1 v/v and the suspension filtered through a syringe filter prior injection) afforded the chalcogenated product as an amorphous solid.

General procedure for arylsulfanylation of nucleosides (dN^I) using copper(I) thiophenolate (Method B):

To a U-shaped microwave vial sealable with a Teflon cap were added dN^{I} (0.255 mmol, 1 equiv.), PhSCu (0.281 mmol, 1.1 equiv.), 2,2'-bipyridyl (9.9 mg, 0.063 mmol, 0.25 equiv.). The vessel was capped and then evacuated and backfilled with Ar three times. DMF (2.1 ml, degassed) was injected via a syringe and the vessel was evacuated and backfilled with Ar and the contents were sonicated. The reaction mixture was heated to 110 °C, vigorously stirred and the consumption of starting nucleoside was carefully monitored by TLC on SiO₂ (CHCl₃/MeOH = 5/1 v/v). The reaction was quenched by addition of MeOH (5 ml), the precipitate was filtered off and the filtrate evaporated to dryness *in vacuo*. The solid residue was either loaded on SiO₂ by co-evaporation from CHCl₃/MeOH, and purified by column chromatography (SiO₂, CHCl₃/MeOH = 5/1 v/v) or reverse phase HPFC (C-18, 0 \rightarrow 100% MeOH in water; solid residue was dissolved in approx. 5 ml DMSO/H₂O=1/1 v/v and the

suspension filtered through a syringe filter prior injection) afforded the unsymmetrical sulphide as an amorphous solid.

5-Phenylsulfanyl-2'-deoxycytidine (dC^{PhS})

Method A - starting from (PhS)₂ (31 mg), conditions: 110 °C, 6 hours. Yield: 50 mg (58 %). White foam.

Method B - starting from PhSCu^I (48.6 mg), conditions: 100 °C, 1.5 hours. Yield: 48 mg (56 %). White foam.



¹H NMR (500.0 MHz, DMSO-*d*₆): 2.06 (dt, 1H, $J_{gem} = 13.1$, $J_{2'b,1'} = J_{2'b,3'} = 6.3$, H-2'b); 2.21 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'a,1'} = 6.3$, $J_{2'a,3'} = 3.9$, H-2'a); 3.54 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'b,OH} = 4.9$, $J_{5'b,4'} = 3.4$, H-5'b); 3.62 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.9$, $J_{5'a,4'} = 3.4$, H-5'a); 3.81 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.4$, H-4'); 4.22 (m, 1H, H-3'); 5.09 (t, 1H, $J_{OH,5'} = 4.9$, OH-5'); 5.24 (d, 1H, $J_{OH,3'} = 4.3$, OH-3'); 6.11 (t, 1H, $J_{1',2'} = 6.3$, H-1'); 6.93 (bs, 1H, NH_aH_b); 7.18 (m, 2H, H-*o*-Ph); 7.19 (m, 1H, H-*p*-Ph); 7.32 (m, 2H, H-*m*-Ph); 7.69 (bs, 1H, NH_aH_b); 8.43 (s, 1H, H-6).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 41.47 (CH₂-2'); 61.30 (CH₂-5'); 70.38 (CH-3'); 86.11 (CH-1'); 87.95 (CH-4'); 94.42 (C-5); 126.47 (CH-*p*-Ph); 126.85 (CH-*o*-Ph); 129.67 (CH-*m*-Ph); 136.59 (C-*i*-Ph); 149.66 (CH-6); 154.75 (C-2); 165.41 (C-4).

MS-ESI (C₁₅H₁₇O₄N₃S) m/z (% int.) calcd: 358.4 [M + Na]⁺. Found: 358.1 [M + Na]⁺ (100), 693.3 [2M + Na]⁺ (60).

HRMS-ESI (C₁₅H₁₇O₄N₃S) *m*/*z* (% int.) calcd: 358.08320 [M + Na]⁺. Found: 358.08331 [M + Na]⁺.

5-[(4-Nitrophenyl)sulfanyl]-2'-deoxycytidine (dC^{NOPS})

Method A - starting from (4-NO₂-PhS)₂ (43.2 mg), conditions: 80 °C, 4.5 hours. Yield: 48.5 mg (50 %). Yellowish microcrystals.



¹H NMR (600.1 MHz, DMSO- d_6): 2.09 (dt, 1H, $J_{gem} = 13.3$,

 $J_{2'b,1'} = J_{2'b,3'} = 6.2, \text{H-2'b}; 2.23 \text{ (ddd, 1H, } J_{gem} = 13.3, J_{2'a,1'} = 6.2, J_{2'a,3'} = 4.1, \text{H-2'a}; 3.52 \text{ (ddd, 1H, } J_{gem} = 11.8, J_{5'b,OH} = 5.0, J_{5'b,4'} = 3.5, \text{H-5'b}; 3.60 \text{ (ddd, 1H, } J_{gem} = 11.8, J_{5'a,OH} = 5.0, J_{5'a,4'} = 3.5, \text{H-5'a}; 3.81 \text{ (q, 1H, } J_{4',3'} = J_{4',5'} = 3.5, \text{H-4'}; 4.21 \text{ (dddd, 1H, } J_{3',2'} = 6.2, 4.1, J_{3',OH} = 4.4, J_{3',4'} = 3.5, \text{H-3'}; 5.03 \text{ (t, 1H, } J_{OH,5'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 1H, } J_{OH,3'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{4',3'} = J_{4',5'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 1H, } J_{OH,3'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{4',3'} = J_{4',5'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 1H, } J_{OH,3'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{4',3'} = J_{4',5'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 1H, } J_{2',4'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{4',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 1H, } J_{2',4'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{4',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 1H, } J_{2',4'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{4',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 1H, } J_{2',4'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 4.4, \text{OH-3'}); 6.10 \text{ (t, 1H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.22 \text{ (d, 2H, } J_{2',4'} = 5.0, \text{OH-5'}); 5.20 \text{ (d, 2H,$

 $J_{1',2'} = 6.2, \text{H}-1'$; 7.07 (bs, 1H, NH_a**H**_b); 7.34 (m, 2H, H-*o*-C₆H₄NO₂); 7.70 (bs, 1H, N**H**_aH_b); 8.15 (m, 2H, H-*m*-C₆H₄NO₂); 8.46 (s, 1H, H-6).

¹³C NMR (150.9 MHz, DMSO-*d*₆): 41.23 (CH₂-2'); 60.85 (CH₂-5'); 69.89 (CH-3'); 86.01 (CH-1'); 87.72 (CH-4'); 91.45 (C-5); 124.30 (CH-*m*-C₆H₄NO₂); 125.82 (CH-*o*-C₆H₄NO₂); 145.25 (C-*p*-C₆H₄NO₂); 147.05 (C-*i*-C₆H₄NO₂); 150.24 (CH-6); 154.34 (C-2); 164.83 (C-4).

MS-ESI (C₁₅H₁₆O₆N₄S) m/z (% int.) calcd: 403.4 [M + Na]⁺. Found: 403.1 [M + Na]⁺ (100), 783.3 [2M + Na]⁺ (30).

HRMS-ESI (C₁₅H₁₆O₆N₄S) *m*/*z* (% int.) calcd: 403.06828 [M + Na]⁺. Found: 403.06835 [M + Na]⁺.

5-[(4-Methoxyphenyl)sulfanyl]-2'-deoxycytidine (dC^{MOPS})

Method A - starting from (4-MeO-PhS)₂ (39.1 mg), conditions: 110 °C, 8 hours. Yield: 20 mg (21 %). White foam.

¹H NMR (600.1 MHz, DMSO-*d*₆): 2.05 (ddd, 1H, $J_{\text{gem}} = 13.1, J_{2'b,1'} = 6.7, J_{2'b,3'} = 5.9, \text{H-2'b}$); 2.20 (ddd, 1H, $J_{\text{gem}} = 13.1, J_{2'a,1'} = 6.0, J_{2'a,3'} = 3.9, \text{H-2'a}$); 3.57,



3.64 (2 × ddd, 2 × 1H, J_{gem} = 11.8, $J_{5',OH}$ = 4.8, $J_{5',4'}$ = 3.5, H-5'); 3.72 (s, 3H, CH₃O); 3.82 (q, 1H, $J_{4',3'}$ = $J_{4',5'}$ = 3.5, H-4'); 4.23 (m, 1H, H-3'); 5.12 (t, 1H, $J_{OH,5'}$ = 4.8, OH-5'); 5.22 (d, 1H, $J_{OH,3'}$ = 4.3, OH-3'); 6.10 (dd, 1H, $J_{1',2'}$ = 6.7, 6.0, H-1'); 6.89 (bs, 1H, NH_aH_b); 6.91 (m, 2H, H-m-C₆H₄OMe); 7.28 (m, 2H, H-o-C₆H₄OMe); 7.67 (bs, 1H, NH_aH_b); 8.43 (s, 1H, H-6).

¹³C NMR (150.9 MHz, DMSO-*d*₆): 41.15 (CH₂-2'); 55.44 (CH₃O); 61.10 (CH₂-5'); 70.15 (CH-3'); 85.77 (CH-1'); 87.67 (CH-4'); 96.71 (C-5); 115.10 (CH-*m*-C₆H₄OMe); 126.12 (C-*i*-C₆H₄OMe); 130.46 (CH-*o*-C₆H₄OMe); 148.50 (CH-6); 154.43 (C-2); 158.74 (C-*p*-C₆H₄OMe); 165.02 (C-4).

MS-ESI (C₁₆H₂₀O₅N₃S) *m*/*z* (% int.) calcd: 388.2 [M + Na]⁺. Found: 388.1 [M + Na]⁺ (100), 753.3 [2M + Na]⁺ (85).

HRMS-ESI ($C_{16}H_{20}O_5N_3S$) *m/z* (% int.) calcd: 366.11182 [M + H]⁺. Found: 366.11198 [M + H]⁺.

5-[(2,4-Dinitrophenyl)sulfanyl]-2'-deoxycytidine (dC^{DNPS})

Method A - starting from (2,4-NO₂-PhS)₂ (50.7 mg), conditions: 85 °C, 2 hours. Yield: 30 mg (28 %). Yellow microcrystals.

¹H NMR (500.0 MHz, DMSO- d_6): 2.12 (dt, 1H, $J_{gem} =$ 13.3, $J_{2'b,1'} = J_{2'b,3'} = 6.2$, H-2'b); 2.25 (ddd, 1H, $J_{gem} =$ 13.3, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 4.3$, H-2'a); 3.53 (ddd, 1H, $J_{gem} =$



11.9, $J_{5'b,OH} = 5.0$, $J_{5'b,4'} = 3.5$, H-5'b); 3.62 (ddd, 1H, $J_{gem} = 11.9$, $J_{5'a,OH} = 5.0$, $J_{5'a,4'} = 3.5$, H-5'a); 3.82 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.5$, H-4'); 4.22 (dddd, 1H, $J_{3',2'} = 6.2$, 4.3, $J_{3',OH} = 4.4$, $J_{3',4'} = 3.5$, H-3'); 5.07 (t, 1H, $J_{OH,5'} = 5.0$, OH-5'); 5.24 (d, 1H, $J_{OH,3'} = 4.4$, OH-3'); 6.11 (t, 1H, $J_{1',2'} = 6.2$, H-1'); 7.14 (bs, 1H, NH_aH_b); 7.47 (d, 1H, $J_{6,5} = 9.0$, H-6-C₆H₃(NO₂)₂); 7.67 (bs, 1H, NH_aH_b); 8.40 (dd, 1H, $J_{5,6} = 9.0$, $J_{5,3} = 2.5$, H-5-C₆H₃(NO₂)₂); 8.53 (s, 1H, H-6); 8.88 (d, 1H, $J_{3,5} = 2.5$, H-3-C₆H₃(NO₂)₂).

¹³C NMR (125.7 MHz, DMSO- d_6): 41.27 (CH₂-2'); 60.81 (CH₂-5'); 69.80 (CH-3'); 86.12 (CH-1'); 87.76 (CH-4'); 91.37 (C-5); 121.31 (CH-3-C₆H₃(NO₂)₂); 127.82 (CH-5-C₆H₃(NO₂)₂); 128.63 (CH-6-C₆H₃(NO₂)₂); 144.68 (C-4-C₆H₃(NO₂)₂); 145.13 (C-1-C₆H₃(NO₂)₂); 145.32 (C-2-C₆H₃(NO₂)₂); 150.50 (CH-6); 154.36 (C-2); 164.18 (C-4).

MS-ESI (C₁₅H₁₅N₅O₈S) m/z (% int.) calcd: 448.4 [M + Na]⁺. Found: 448.1 [M + Na]⁺ (100), 873.1 [2M + Na]⁺ (55).

HRMS-ESI (C₁₅H₁₅N₅O₈S) *m*/*z* (% int.) calcd: 448.05335 [M + Na]⁺. Found: 448.05347 [M + Na]⁺.

5-[(2-Thienyl)sulfanyl]-2'-deoxycytidine (dC^{ThS})

Method A - starting from bis(2-thienyl)disulfide (32.3 mg), conditions: 90 °C, 2 hours. Yield: 40 mg (46 %). White foam.

¹H NMR (500.0 MHz, DMSO-*d*₆): 2.00 (dt, 1H, $J_{gem} = 13.1$, $J_{2'b,1'} = J_{2'b,3'} = 6.2$, H-2'b); 2.19 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.9$, H-2'a); 3.59 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'b,OH} = 4.8$, $J_{5'b,4'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,4'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, J_{gem} = 11.8, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, J_{gem} = 11.8, $J_{5'a,OH} = 4.8$, $J_{5'a,A'} = 3.5$, H-5'b); 3.66 (ddd, 1H, J_{gem} = 11.8, $J_{5'a,OH} = 3.5$, H-5'b); 3.66 (ddd, 1H, J_{gem} = 11.8, $J_{5'a,OH} = 3.5$, H-5'b); 3.66 (ddd, 1H, J_{gem} = 3.5, H-5'b); 3.57 (ddd, 1H, J_{g



= 3.5, H-5'a); 3.83 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.5$, H-4'); 4.23 (dddd, 1H, $J_{3',2'} = 6.2$, 3.9, $J_{3',OH} = 4.3$, $J_{3',4'} = 3.5$, H-3'); 5.17 (t, 1H, $J_{OH,5'} = 4.8$, OH-5'); 5.25 (d, 1H, $J_{OH,3'} = 4.3$, OH-3'); 6.08 (t, 1H,

 $J_{1',2'} = 6.2, \text{H-1'}$; 7.01 (dd, 1H, $J_{4,5} = 5.3, J_{4,3} = 3.6, \text{H-4-thienyl}$); 7.16 (bs, 1H, NH_aH_b); 7.32 (dd, 1H, $J_{3,4} = 3.6, J_{3,5} = 1.3, \text{H-3-thienyl}$); 7.58 (dd, 1H, $J_{5,4} = 5.3, J_{5,3} = 1.3, \text{H-5-thienyl}$); 7.83 (bs, 1H, NH_aH_b); 8.50 (s, 1H, H-6).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 41.26 (CH₂-2'); 61.12 (CH₂-5'); 70.13 (CH-3'); 85.91 (CH-1'); 87.73 (CH-4'); 98.74 (br, C-5); 128.11 (CH-4-thienyl); 130.21 (CH-5-thienyl); 132.46 (CH-3-thienyl); 134.44 (C-2-thienyl); 148.41 (CH-6); 154.18 (C-2); 164.58 (C-4).

MS-ESI (C₁₃H₁₅O₄N₃S₂) *m/z* (% int.) calcd: 364.4 [M + Na]⁺. Found: 364.2 [M + Na]⁺ (100), 705.5 [2M + Na]⁺ (80).

HRMS-ESI ($C_{13}H_{15}O_4N_3S_2$) *m/z* (% int.) calcd: 364.03962 [M + Na]⁺. Found: 364.03967 [M + Na]⁺.

5-Phenylselanyl-2'-deoxycytidine (dC^{PhSe})

Method A - starting from $(PhSe)_2$ (39.9 mg), conditions: 80 °C, 1.5 hours. Yield: 54 mg (50 %). White foam, which was recrystallized from water/MeOH.

¹H NMR (500.0 MHz, DMSO-*d*₆): 2.05 (dt, 1H, $J_{gem} = 13.2$, $J_{2'b,1'} = J_{2'b,3'} = 6.3$, H-2'b); 2.21 (ddd, 1H, $J_{gem} = 13.2$, $J_{2'a,1'} = 6.3$, $J_{2'a,3'} = 3.7$, H-2'a); 3.55 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'b,OH} = 4.9$, $J_{5'b,4'} =$

3.7, H-5'b); 3.62 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 4.9$, $J_{5'a,4'} = 3.7$, H-5'a); 3.82 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.7$, H-4'); 4.23 (m, 1H, H-3'); 5.08 (t, 1H, $J_{OH,5'} = 4.9$, OH-5'); 5.23 (d, 1H, $J_{OH,3'} = 4.3$, OH-3'); 6.13 (t, 1H, $J_{1',2'} = 6.3$, H-1'); 6.74 (bs, 1H, NH_aH_b); 7.24 (m, 1H, H-*p*-Ph); 7.30 (m, 2H, H-*m*-Ph); 7.34 (m, 2H, H-*o*-Ph); 7.71 (bs, 1H, NH_aH_b); 8.45 (s, 1H, H-6).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 41.15 (CH₂-2'); 61.11 (CH₂-5'); 70.20 (CH-3'); 85.76 (CH-1'); 87.67 (CH-4'); 91.40 (C-5); 126.93 (CH-*p*-Ph); 129.45 (CH-*o*-Ph); 129.64 (CH-*m*-Ph); 131.44 (C-*i*-Ph); 149.79 (CH-6); 154.62 (C-2); 165.18 (C-4).

⁷⁷Se NMR (95.4 MHz, DMSO-*d*₆): 283.80.

MS-ESI (C₁₅H₁₇O₄N₃Se) m/z (% int.) calcd: 406.0 [M + Na]⁺. Found: 406.1 [M + Na]⁺ (100), 787.2 [2M + Na]⁺ (10).

HRMS-ESI (C₁₅H₁₇O₄N₃Se) m/z (% int.) calcd: 406.02765 [M + Na]⁺. Found: 406. 02783 [M + Na]⁺.



5-Methylselanyl-2'-deoxycytidine (dC^{MeSe})

Method A - starting from (MeSe)₂ (1.05 equiv., 50 mg, 25 μ l), conditions: 85 °C, 3 hours. The compound was separated using column chromatography and HPLC (C-18, 0 \rightarrow 100% MeOH in water). The compound was freeze-dried from H₂O. Yield: 15 mg (18 %). White microcrystals.



¹H NMR (500.0 MHz, DMSO-*d*₆): 2.00 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'b,1'} = 7.0$, $J_{2'b,3'} = 6.0$, H-2'b); 2.11 (s, 3H, CH₃Se); 2.13 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'a,1'} = 6.1$, $J_{2'a,3'} = 3.7$, H-2'a); 3.54 (dd, 1H, $J_{gem} = 11.8$, $J_{5'b,4'} = 3.7$, H-5'b); 3.61 (dd, 1H, $J_{gem} = 11.8$, $J_{5'a,4'} = 3.7$, H-5'a); 3.78 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.7$, H-4'); 4.21 (dt, 1H, $J_{3',2'} = 6.0$, 3.7, $J_{3',4'} = 3.7$, H-3'); 6.10 (dd, 1H, $J_{1',2'} = 7.0$, 6.1, H-1'); 6.78, 7.69 (2 × bs, 2 × 1H, NH₂); 8.20 (s, 1H, H-6).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 9.41 (CH₃Se); 40.94 (CH₂-2'); 61.24 (CH₂-5'); 70.33 (CH-3'); 85.42 (CH-1'); 87.55 (CH-4'); 92.35 (C-5); 147.26 (CH-6); 154.72 (C-2); 165.18 (C-4).

⁷⁷Se NMR (95.4 MHz, DMSO- d_6): 89.74 (q, $J_{Se,H} = 10.9$).

MS-ESI ($C_{10}H_{15}O_4N_3Se$) *m/z* (% int.) calcd: 344.0 [M + Na]⁺. Found: 344.1 [M + Na]⁺ (100), 665.3 [2M + Na]⁺ (50).

HRMS-ESI ($C_{10}H_{15}O_4N_3Se$) *m/z* (% int.) calcd: 344.01200 [M + Na]⁺. Found: 344.01215 [M + Na]⁺.

5-Phenylsulfanyl-2'-deoxyuridine (dUPhS)S1

Method B - starting from PhSCu^I (48.3 mg), conditions: 85 °C, 1.5 hours. Yield: 40.5 mg (47 %). White foam.

The compound is described ref. ^{S1} and the data are in accordance with the literature.



¹H NMR (500.0 MHz, DMSO- d_6): 2.16 (ddd, 1H, $J_{gem} = 13.2$,

 $J_{2'b,1'} = 6.5, J_{2'b,3'} = 4.5, H-2'b)$; 2.20 (ddd, 1H, $J_{gem} = 13.2, J_{2'a,1'} = 6.7, J_{2'a,3'} = 5.4, H-2'a)$; 3.54, 3.60 (2 × bdd, 2 × 1H, $J_{gem} = 11.8, J_{5',4'} = 3.4, H-5'$); 3.81 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.4, H-4'$); 4.24 (bm, 1H, H-3'); 5.09 (bs, 1H, OH-5'); 5.26 (bs, 1H, OH-3'); 6.14 (dd, 1H, $J_{1',2'} = 6.7, 6.5, H-1'$); 7.16 (m, 1H, H-*p*-Ph); 7.19 (m, 2H, H-*o*-Ph); 7.29 (m, 2H, H-*m*-Ph); 8.44 (s, 1H, H-6); 11.65 (bs, 1H, NH).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 40.50 (CH₂-2'); 61.03 (CH₂-5'); 70.19 (CH-3'); 85.21 (CH-1'); 87.80 (CH-4'); 103.62 (C-5); 125.84 (CH-*p*-Ph); 126.62 (CH-*o*-Ph); 129.18 (CH-*m*-Ph); 136.54 (C-*i*-Ph); 146.94 (CH-6); 150.45 (C-2); 161.49 (C-4).

MS-ESI (C₁₅H₁₆O₅N₂S) m/z (% int.) calcd: 359.4 [M + Na]⁺. Found: 359.0 [M + Na]⁺ (100), 695.1 [2M + Na]⁺ (35).

HRMS-ESI ($C_{15}H_{16}O_5N_2S$) *m*/*z* (% int.) calcd: 359.06721 [M + Na]⁺. Found: 359.06730 [M + Na]⁺.

5-[(2-Thienyl)sulfanyl]-2'-deoxyuridine (dU^{ThS})

Method A - starting from bis(2-thienyl)disulfide (32.3 mg), conditions: 85 °C, 1.5 hours. Yield: 22.5 mg (26 %). White foam.

¹H NMR (500.0 MHz, DMSO- d_6): 2.08 (ddd, 1H, $J_{gem} = 13.4$, $J_{2'b,1'} = 7.0$, $J_{2'b,3'} = 5.9$, H-2'b); 2.14 (ddd, 1H, $J_{gem} = 13.4$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.6$, H-2'a); 3.51 (bdd, 1H, $J_{gem} = 11.7$,



 $J_{5'b,4'} = 3.6, \text{H-5'b}$; 3.56 (bdd, 1H, $J_{\text{gem}} = 11.7, J_{5'a,4'} = 3.6, \text{H-5'a}$); 3.80 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.6, \text{H-4'}$); 4.23 (dt, 1H, $J_{3',2'} = 5.9, 3.6, J_{3',4'} = 3.6, \text{H-3'}$); 5.09 (bs, 1H, OH-5'); 5.25 (bs, 1H, OH-3'); 6.09 (dd, 1H, $J_{1',2'} = 7.0, 6.2, \text{H-1'}$); 7.00 (dd, 1H, $J_{4,5} = 5.3, J_{4,3} = 3.6, \text{H-4-thienyl}$); 7.22 (dd, 1H, $J_{3,4} = 3.6, J_{3,5} = 1.3, \text{H-3-thienyl}$); 7.60 (dd, 1H, $J_{5,4} = 5.3, J_{5,3} = 1.3, \text{H-5-thienyl}$); 8.25 (s, 1H, H-6); 11.64 (bs, 1H, NH).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 40.35 (CH₂-2'); 61.18 (CH₂-5'); 70.31 (CH-3'); 85.12 (CH-1'); 87.78 (CH-4'); 108.15 (C-5); 128.08 (CH-4-thienyl); 130.46 (CH-5-thienyl); 132.75 (C-2-thienyl); 133.31 (CH-3-thienyl); 143.90 (CH-6); 150.14 (C-2); 161.18 (C-4).

MS-ESI ($C_{13}H_{14}O_5N_2S_2$) *m/z* (% int.) calcd: 365.4 [M + Na]⁺. Found: 365.0 [M + Na]⁺ (100), 707.0 [2M + Na]⁺ (90).

HRMS-ESI ($C_{13}H_{14}O_5N_2S_2$) *m/z* (% int.) calcd: 365.02363 [M + Na]⁺. Found: 365.02377 [M + Na]⁺.

5-Phenylselanyl-2'-deoxyuridine (dU^{PhSe}) ^{S2}

Method A - starting from (PhSe)₂ (43.6 mg), conditions: 85 °C, 1.5 hours. Yield: 23.5 mg (24 %). White foam.



The compound is described in ref.^{S2} however, the compound was not characterized sufficiently.

¹H NMR (500.0 MHz, DMSO-*d*₆): 2.12 (ddd, 1H, $J_{gem} = 13.3$, $J_{2'b,1'} = 7.0$, $J_{2'b,3'} = 5.7$, H-2'b); 2.15 (ddd, 1H, $J_{gem} = 13.3$, $J_{2'a,1'} = 6.3$, $J_{2'a,3'} = 4.0$, H-2'a); 3.47, 3.52 (2 × bdd, 2 × 1H, $J_{gem} = 11.8$, $J_{5',4'} = 3.5$, H-5'); 3.79 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.5$, H-4'); 4.20 (ddd, 1H, $J_{3',2'} = 5.7$, 4.0, $J_{3',4'} = 3.5$, H-3'); 5.03 (bs, 1H, OH-5'); 5.24 (bs, 1H, OH-3'); 6.13 (dd, 1H, $J_{1',2'} = 7.0$, 6.3, H-1'); 7.24 (m, 1H, H-*p*-Ph); 7.29 (m, 2H, H-*m*-Ph); 7.36 (m, 2H, H-*o*-Ph); 8.28 (s, 1H, H-6); 11.61 (bs, 1H, NH).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 40.33 (CH₂-2'); 61.15 (CH₂-5'); 70.34 (CH-3'); 85.01 (CH-1'); 87.73 (CH-4'); 101.36 (C-5); 126.86 (CH-*p*-Ph); 129.51 (CH-*m*-Ph); 130.20 (CH-*o*-Ph); 131.04 (C-*i*-Ph); 146.07 (CH-6); 150.56 (C-2); 161.67 (C-4).

⁷⁷Se NMR (95.4 MHz, DMSO-*d*₆): 310.06.

MS-ESI (C₁₅H₁₆O₅N₂Se) m/z (% int.) calcd: 407.0 [M + Na]⁺. Found: 407.1 [M + Na]⁺ (100), 791.0 [2M + Na]⁺ (40).

HRMS-ESI (C₁₅H₁₆O₅N₂Se) m/z (% int.) calcd: 407.01166 [M + Na]⁺. Found: 407.01184 [M + Na]⁺.

5-Methylselanyl-2'-deoxyuridine (dU^{MeSe})^{S3}





The compound is described in ref. ^{S3} and the data are in accordance with the literature.

¹H NMR (500.0 MHz, DMSO-*d*₆): 2.10 (ddd, 1H, $J_{gem} = 13.3$, $J_{2'b,1'} = 6.3$, $J_{2'b,3'} = 3.6$, H-2'b); 2.13 (s, 3H, CH₃Se); 2.15 (ddd, 1H, $J_{gem} = 13.3$, $J_{2'a,1'} = 7.2$, $J_{2'a,3'} = 5.7$, H-2'a); 3.57, 3.61 (2 × dd, 2×1 H, $J_{gem} = 11.8$, $J_{5',4'} = 3.2$, H-5'); 3.80 (q, 1H, $J_{4',3'} = J_{4',5'} = 3.2$, H-4'); 4.26 (ddd, 1H, $J_{3',2'} = 5.6$, 3.6, $J_{3',4'} = 3.2$, H-3'); 5.11, 5.25 ($2 \times bs$, 2×1 H, OH-3',5'); 6.18 (dd, 1H, $J_{1',2'} = 7.2$, 6.3, H-1'); 7.83 (s, 1H, H-6); 11.52 (bs, 1H, NH).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 5.42 (CH₃Se); 40.24 (CH₂-2'); 61.26 (CH₂-5'); 70.57 (CH-3'); 84.73 (CH-1'); 87.70 (CH-4'); 104.21 (C-5); 137.75 (CH-6); 150.23 (C-2); 161.87 (C-4).

⁷⁷Se NMR (95.4 MHz, DMSO- d_6): 125.98 (q, $J_{Se,H} = 11.4$).

MS-ESI (C₁₀H₁₄O₅N₂Se) m/z (% int.) calcd: 345.0 [M + Na]⁺. Found: 345.0 [M + Na]⁺ (100), 667.0 [2M + Na]⁺ (35).

HRMS-ESI ($C_{10}H_{14}O_5NaN_2Se$) m/z (% int.) calcd: 344.99601 [M + Na]⁺. Found: 344.99612 [M + Na]⁺.

7-Phenylsulfanyl-7-deaza-2'-deoxyadenosine (dA^{PhS})

Method B - starting from PhSCu^I (45.7 mg), conditions: 110 °C, 1.5 hours. Yield: 34 mg (40 %). White foam.

¹H NMR (500.0 MHz, DMSO-*d*₆): 2.23 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'b,1'} = 6.0$, $J_{2'b,3'} = 2.8$, H-2'b); 2.54 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'a,1'} = 8.0$, $J_{2'a,3'} = 5.8$, H-2'a); 3.53 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'b,OH} = 5.9$, $J_{5'b,4'} = 4.2$, H-5'b); 3.60 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = 5.2$, $J_{5'a,4'} = 4.4$, H-5'a); 3.85



(ddd, 1H, $J_{4',5'} = 4.4, 4.2, J_{4',3'} = 2.5, H-4'$); 4.37 (dddd, 1H, $J_{3',2'} = 5.8, 2.8, J_{3',OH} = 4.1, J_{3',4'} = 2.5, H-3'$); 5.09 (dd, 1H, $J_{OH,5'} = 5.9, 5.2, OH-5'$); 5.29 (d, 1H, $J_{OH,3'} = 4.1, OH-3'$); 6.55 (dd, 1H, $J_{1',2'} = 8.0, 6.0, H-1'$); 7.12 (m, 2H, H-*o*-Ph); 7.15 (m, 1H, H-*p*-Ph); 7.29 (m, 2H, H-*m*-Ph); 7.88 (s, 1H, H-6); 8.14 (s, 1H, H-2).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 40.17 (CH₂-2'); 62.01 (CH₂-5'); 71.10 (CH-3'); 83.58 (CH-1'); 87.77 (CH-4'); 99.37 (C-5); 103.26 (C-4a); 125.90 (CH-*p*-Ph); 126.00 (CH-*o*-Ph); 129.47 (CH-*m*-Ph); 129.82 (CH-6); 138.29 (C-*i*-Ph); 150.81 (C-7a); 152.75 (CH-2); 157.60 (C-4).

MS-ESI (C₁₇H₁₈O₃N₄S) m/z (% int.) calcd: 381.1 [M + Na]⁺. Found: 381.2 [M + Na]⁺ (100).

HRMS-ESI ($C_{17}H_{18}O_3NaN_4S$) m/z (% int.) calcd: 381.09918 [M + Na]⁺. Found: 381.09932 [M + Na]⁺.

7-Phenylselanyl-7-deaza-2'-deoxyadenosine (dA^{PhSe})

Method A - starting from (PhSe)₂ (37.4 mg), conditions: 90 °C, 1.5 hours. Yield: 31 mg (32 %). White foam.

¹H NMR (500.0 MHz, DMSO-*d*₆): 2.22 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'b,1'} = 6.0$, $J_{2'b,3'} = 2.7$, H-2'b); 2.55 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'a,1'} = 8.1$, $J_{2'a,3'} = 5.7$, H-2'a); 3.52 (ddd, 1H, $J_{gem} = 11.7$, $J_{5'b,OH} = 5.9$, $J_{5'b,4'} = 4.2$, H-5'b); 3.60 (ddd, 1H, $J_{gem} = 11.5$, $J_{5'a,OH} = 5.3$, $J_{5'a,4'} = 4.8$, H-5'a); 3.85



(ddd, 1H, $J_{4',5'} = 4.8$, 4.2, $J_{4',3'} = 2.4$, H-4'); 4.36 (dddd, 1H, $J_{3',2'} = 5.7$, 2.7, $J_{3',OH} = 4.0$, $J_{3',4'} = 2.4$, H-3'); 5.11 (dd, 1H, $J_{OH,5'} = 5.9$, 5.3, OH-5'); 5.30 (d, 1H, $J_{OH,3'} = 4.0$, OH-3'); 6.54 (dd, 1H, $J_{1',2'} = 8.1$, 5.9, H-1'); 7.19 (m, 1H, H-*p*-Ph); 7.22 - 7.30 (m, 4H, H-*o*,*m*-Ph); 7.86 (s, 1H, H-6); 8.14 (s, 1H, H-2).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 40.15 (CH₂-2'); 62.07 (CH₂-5'); 71.19 (CH-3'); 83.59 (CH-1'); 87.78 (CH-4'); 93.56 (C-5); 103.72 (C-4a); 126.63 (CH-*p*-Ph); 128.68 (CH-*o*-Ph); 129.77 (CH-*m*-Ph); 130.19 (CH-6); 133.28 (C-*i*-Ph); 150.67 (C-7a); 152.54 (CH-2); 157.77 (C-4).

⁷⁷Se NMR (95.4 MHz, DMSO-*d*₆): 230.26.

MS-ESI (C₁₇H₁₈O₃N₄Se) m/z (% int.) calcd: 429.0 [M + Na]⁺. Found: 429.1 [M + Na]⁺ (100), 835.3 [2M + Na]⁺ (35).

HRMS-ESI ($C_{17}H_{18}O_3N_4Se$) *m/z* (% int.) calcd: 429.04363 [M + Na]⁺. Found: 429.04370 [M + Na]⁺.

7-Methylselanyl-7-deaza-2'-deoxyadenosine (dA^{MeSe})

Method A - starting from $(MeSe)_2$ (1.1 equiv., 50 mg, 25 µl), conditions: 100 °C, 3.5 hours. The compound was separated using HPFC and HPLC (C-18, 0 \rightarrow 100% MeOH in water). The compound was freeze-dried from H₂O. Yield: 11.4 mg (14 %). White microcrystals.



¹H NMR (500.0 MHz, DMSO-*d*₆): 2.16 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'b,1'} = 6.0$, $J_{2'b,3'} = 2.7$, H-2'b); 2.19 (s, 3H, CH₃Se); 2.50 (ddd, 1H, $J_{gem} = 13.1$, $J_{2'a,1'} = 8.3$, $J_{2'a,3'} = 5.8$, H-2'a); 3.52 (ddd, 1H, $J_{gem} = 11.8$, $J_{5'b,OH} = 5.4$, $J_{5'b,4'} = 4.3$, H-5'b); 3.58 (dt, 1H, $J_{gem} = 11.8$, $J_{5'a,OH} = J_{5'a,4'} = 4.6$, H-5'a); 3.83 (ddd, 1H, $J_{4',5'} = 4.6$, 4.3, $J_{4',3'} = 2.5$, H-4'); 4.34 (dddd, 1H, $J_{3',2'} = 5.8$, 2.7, $J_{3',OH} =$ 3.9, $J_{3',4'} = 2.5$, H-3'); 5.11 (bdd, 1H, $J_{OH,5'} = 5.4$, 4.6, OH-5'); 5.27 (bd, 1H, $J_{OH,3'} = 4.9$, OH-3'); 6.49 (dd, 1H, $J_{1',2'} = 8.3$, 6.0, H-1'); 7.60 (s, 1H, H-6); 8.11 (s, 1H, H-2).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 12.12 (CH₃Se); 40.03 (CH₂-2'); 62.15 (CH₂-5'); 71.23 (CH-3'); 83.36 (CH-1'); 87.66 (CH-4'); 96.05 (C-5); 103.72 (C-4a); 127.83 (CH-6); 150.25 (C-7a); 152.29 (CH-2); 157.89 (C-4).

⁷⁷Se NMR (95.4 MHz, DMSO- d_6): 33.61 (q, $J_{Se,H} = 10.8$).

MS-ESI ($C_{12}H_{16}O_3N_4Se$) m/z (% int.) calcd: 345.0 [M + H]⁺. Found: 345.0 [M + H]⁺ (100).

HRMS-ESI (C₁₂H₁₆O₃N₄Se) *m*/*z* (% int.) calcd: 345.04604 [M + H]⁺. Found: 345.04615 [M + H]⁺.

7-Phenylsulfanyl-7-deaza-2'-deoxyguanosine (dGPhS)

Method B - starting from PhSCu^I (43.7 mg), conditions: 110 °C, 1.5 hours. Yield: 33.5 mg (39 %). White foam.

¹H NMR (500.0 MHz, DMSO-*d*₆): 2.12 (ddd, 1H, $J_{gem} = 13.0, J_{2'b,1'} = 5.8, J_{2'b,3'} = 2.5, H-2'b$); 2.35 (ddd, 1H, $J_{gem} = 13.0, J_{2'a,1'} = 8.4, J_{2'a,3'} = 5.7, H-2'a$); 3.48, 3.52 (2 × dt, 1H,

 $J_{\text{gem}} = 11.7, J_{5',\text{OH}} = J_{5',4'} = 4.6, \text{H-5'}$; 3.77 (ddd, 1H, $J_{4',5'} = 4.6, J_{4',3'} = 2.5, \text{H-4'}$); 4.29 (dq, 1H, $J_{3',2'} = 5.7, 2.5, J_{3',4'} = J_{3',\text{OH}} = 2.5, \text{H-3'}$); 4.91 (bt, 1H, $J_{\text{OH},5'} = 4.6, \text{OH-5'}$); 5.22 (bd, 1H, $J_{\text{OH},3'} = 2.5, \text{OH-3'}$); 6.32 (dd, 1H, $J_{1',2'} = 8.4, 5.8, \text{H-1'}$); 6.37 (bs, 2H, NH₂); 7.08 (m, 1H, H-*p*-Ph); 7.10 (m, 2H, H-*o*-Ph); 7.22 (m, 2H, H-*m*-Ph); 7.25 (s, 1H, H-6); 10.42 (bs, 1H, NH).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 39.97 (CH₂-2'); 62.04 (CH₂-5'); 71.11 (CH-3'); 82.59 (CH-1'); 87.38 (CH-4'); 100.39 (C-5); 103.73 (C-4a); 123.46 (CH-6); 124.97 (CH-*p*-Ph); 126.12 (CH-*o*-Ph); 128.88 (CH-*m*-Ph); 139.56 (C-*i*-Ph); 152.02 (C-7a); 153.41 (C-2); 157.96 (C-4).

MS-ESI ($C_{17}H_{18}O_4N_4S$) m/z (% int.) calcd: 397.4 [M + Na]⁺. Found: 397.1 [M + Na]⁺ (100).

HRMS-ESI (C₁₇H₁₈O₄N₄S) *m*/*z* (% int.) calcd: 397.09410 [M + Na]⁺. Found: 397.09420 [M + Na]⁺.



7-Phenylselanyl-7-deaza-2'-deoxyguanosine (dG^{PhSe})

Method A - starting from $(PhSe)_2$ (39.6 mg), conditions: 80 °C, 1.5 hours. Yield: 43.2 mg (45 %). White foam.



8.5, $J_{2'a,3'} = 5.6$, H-2'a); 3.45 (ddd, 1H, $J_{gem} = 11.5$, $J_{5'b,OH} = 5.3$, $J_{5'b,4'} = 4.5$, H-5'b); 3.49 (ddd, 1H, $J_{gem} = 11.5$, $J_{5'a,OH} = 5.3$, $J_{5'a,A'} = 4.5$, H-5'a); 3.75 (td, 1H, $J_{4',5'} = 4.5$, $J_{4',3'} = 2.3$, H-4'); 4.26 (m, 1H, H-3'); 4.91 (t, 1H, $J_{OH,5'} = 5.3$, OH-5'); 5.23 (d, 1H, $J_{OH,3'} = 3.7$, OH-3'); 6.31 (dd, 1H, $J_{1',2'} = 8.5$, 5.8, H-1'); 6.36 (bs, 2H, NH₂); 7.13 (s, 1H, H-6); 7.15 (m, 1H, H-*p*-Ph); 7.22 (m, 2H, H-*m*-Ph); 7.30 (m, 2H, H-*o*-Ph); 10.43 (bs, 1H, NH).

¹³C NMR (125.7 MHz, DMSO-*d*₆): 39.93 (CH₂-2'); 62.09 (CH₂-5'); 71.18 (CH-3'); 82.57 (CH-1'); 87.37 (CH-4'); 98.19 (C-5); 100.87 (C-4a); 123.30 (CH-6); 126.08 (CH-*p*-Ph); 129.27 (CH*o*-Ph); 129.43 (CH-*m*-Ph); 133.95 (C-*i*-Ph); 151.90 (C-7a); 153.25 (C-2); 158.28 (C-4).

⁷⁷Se NMR (95.4 MHz, DMSO-*d*₆): 262.71.

MS-ESI ($C_{17}H_{18}O_4N_4Se$) m/z (% int.) calcd: 423.1 [M + H]⁺. Found: 423.1 [M + H]⁺ (30).

HRMS-ESI (C₁₇H₁₈O₄N₄Se) *m*/*z* (% int.) calcd: 423.05660 [M + H]⁺. Found: 423.05658 [M + H]⁺.

dG^{PhSe}

ÓН

General procedure for copper-mediated sulfanylations and selanylations of dC^IMP (Method A):

To a U-shaped microwave vial sealable with a Teflon cap were added Cu powder (91.5 mg, 1.440 mmol, 10 equiv.), 2,2'-bipyridyl (74.3 mg, 0.476 mmol, 3.30 equiv.) and corresponding diselenide or disulfide (0.721 mmol, 5 equiv.). The vessel was capped and then evacuated and backfilled with Ar three times. Triethylammonium salt (TEA⁺) of **dC^IMP** (77 mg, 0.144 mmol, 1 equiv.) in DMF (1.1 ml, degassed) was injected via a syringe and the vessel was evacuated and backfilled with Ar and the contents were sonicated. The reaction mixture was heated to 80 °C and vigorously stirred for 60 - 70 minutes. The reaction was quenched by slow addition of cold water (5 ml), the precipitate was filtered off and the filtrate evaporated to dryness *in vacuo*. The product was purified by reverse phase HPLC [C-18, 0 \rightarrow 90% MeOH in 0.1M aq. TEAB (triethylammonium bicarbonate); solid residue was dissolved in approx. 5 ml H₂O and filtered through two syringe filters prior injection]. Several co-evaporations with water, conversion into a sodium form (Dowex 50WX8 in Na⁺ cycle followed by Chelex 100 resin in Na⁺ cycle^[X2]) followed by freeze-drying from water afforded the product as a white, fluffy powder.

General procedure for monophosphorylation of S- or Se-linked nucleosides dC^{RX} (Method B):

To an argon-purged flask containing under reduced presure dried (2 hours, 80 °C) dC^{RX} (0.1-0.2 mmol), dry PO(OMe)₃ (0.1 ml for every 10 mg of dC^{RX}) was added and the suspension/solution cooled to 0 °C on an ice bath. Freshly distilled POCl₃ (1.3 equiv. – 1.5 equiv.) was slowly added with a Hamilton syringe, the reaction was stirred for 80 – 180 minutes and monitored with TLC (eluent 11 iPrOH : 2 H₂O : 7 NH₄OH). The reaction was quenched with 2M TEAB (1 ml) and evaporated to dryness. The product was purified by reverse phase HPLC (C-18, 0 \rightarrow 90% MeOH in 0.1M aq. TEAB). Several co-evaporations with water, conversion into a sodium form (Dowex 50WX8 in Na⁺ cycle) followed by freeze-drying from water afforded the product as a fluffy powder.

5-Phenylsulfanyl-2'-deoxycytidine 5'-*O*-monophosphate sodium salt (dC^{PhS}MP)

Method A starting from (PhS)₂ (222.2 mg). Yield: 2.9 mg (5 %). White solid.

Method B: dC^{PhS} (100 mg, 0.3 mmol), POCl₃ (59.4 mg, 36 μ l, 0.39 mmol, 1.3 equiv.), 70 minutes. Yield: 55 mg (43 %). White solid.



¹H NMR (500.0 MHz, D₂O): 2.36 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'b,1'} = 7.4$, $J_{2'b,3'} = 6.4$, H-2'b); 2.46 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.6$, H-2'a); 3.92 (ddd, 1H, $J_{gem} = 11.3$, $J_{H,P} = 5.1$, $J_{5'b,4'} = 4.8$, H-5'b); 3.96 (ddd, 1H, $J_{gem} = 11.3$, $J_{H,P} = 5.9$, $J_{5'a,4'} = 4.8$, H-5'a); 4.18 (td, 1H, $J_{4',5'} = 4.8$, $J_{4',3'} = 3.4$, H-4'); 4.53 (ddd, 1H, $J_{3',2'} = 6.5$, 3.6, $J_{3',2'} = 3.4$, H-3'); 6.28 (dd, 1H, $J_{1',2'} = 7.4$, 6.2, H-1'); 7.22-7.30 (m, 3H, H-*o*,*p*-Ph); 7.35 (m, 2H, H-*m*-Ph); 8.30 (s, 1H, H-6).

¹³C NMR (125.7 MHz, D₂O): 41.87 (CH₂-2'); 66.62 (d, $J_{C,P} = 4.6$, CH₂-5'); 73.81 (CH-3'); 88.74 (d, $J_{C,P} = 8.2$, CH-4'); 89.14 (CH-1'); 100.62 (C-5); 129.24 (CH-*o*-Ph); 129.32 (CH-*p*-Ph); 132.21 (CH-*m*-Ph); 137.24 (C-*i*-Ph); 151.64 (CH-6); 159.73 (C-2); 168.43 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): 3.87.

MS-ESI (C₁₅H₁₇O₇N₃PS⁻) *m/z* (% int.) calcd: 414.3 [M]. Found: 414.0 [M] (100).

HRMS-ESI (C₁₅H₁₇O₇N₃PS⁻) *m/z* (% int.) calcd: 414.05303 [M]. Found: 414.05266 [M].

5-[(4-Nitrophenyl)sulfanyl]-2'-deoxycytidine 5'-*O*-monophosphate sodium salt (dC^{NOPS}MP)





Method B: dC^{NOPhS} (59 mg, 0.16 mmol), POCl₃

(30.9 mg, 18.9 µl, 0.2 mmol, 1.3 equiv.), 80 minutes. Yield: 20 mg (27 %). Yellowish solid.

¹H NMR (500.0 MHz, D₂O): 2.37 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'b,1'} = 7.3$, $J_{2'b,3'} = 6.6$, H-2'b); 2.48 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.6$, H-2'a); 3.93 (ddd, 1H, $J_{gem} = 11.4$, $J_{H,P} = 5.2$, $J_{5'b,4'} = 4.7$, H-5'b); 3.60 (ddd, 1H, $J_{gem} = 11.4$, $J_{H,P} = 5.8$, $J_{5'a,4'} = 4.7$, H-5'a); 4.18 (td, 1H, $J_{4',5'} = 4.7$, $J_{4',3'} = 3.6$, H-4'); 4.53 (dt, 1H, $J_{3',2'} = 6.6$, 3.6, $J_{3',4'} = 3.6$, H-3'); 6.27 (dd, 1H, $J_{1',2'} = 7.3$, 6.2, H-1'); 7.34 (m, 2H, H-o-C₆H₄NO₂); 8.14 (m, 2H, H-m-C₆H₄NO₂); 8.36 (s, 1H, H-6).

¹³C NMR (125.7 MHz, D₂O): 42.04 (CH₂-2'); 66.58 (d, $J_{C,P} = 4.6$, CH₂-5'); 73.76 (CH-3'); 88.82 (d, $J_{C,P} = 8.3$, CH-4'); 89.35 (CH-1'); 98.15 (C-5); 127.06 (CH-*m*-C₆H₄NO₂); 128.45 (CH-*o*-C₆H₄NO₂); 147.99 (C-*i*-C₆H₄NO₂); 148.22 (C-*p*-C₆H₄NO₂); 152.65 (CH-6); 159.60 (C-2); 168.17 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): 3.79.

MS-ESI (C₁₅H₁₆O₉N₄PS⁻) *m/z* (% int.) calcd: 459.3 [M]. Found: 459.0 [M] (100).

HRMS-ESI (C₁₅H₁₆O₉N₄PS⁻) *m/z* (% int.) calcd: 459.03811 [M]. Found: 459.03751 [M].

5-[(4-Methoxyphenyl)sulfanyl]-2'-deoxycytidine 5'-*O*-monophosphate sodium salt (dC^{MOPS}MP)

Method B: **dC**^{MOPS} (32 mg, 0.09 mmol), POCl₃ (17.4 mg, 10.5 μl, 0.117 mmol, 1.3 equiv.), 90 minutes. Yield: 9 mg (22 %). White solid.

¹H NMR (500.0 MHz, D₂O): 2.36 (ddd, 1H, $J_{gem} =$ 14.0, $J_{2'b,1'} = 7.5$, $J_{2'b,3'} = 6.5$, H-2'b); 2.44 (ddd, 1H, $J_{gem} =$ 14.0, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.6$, H-2'a); 3.80 (s,



3H, CH₃O); 3.91 (dt, 1H, $J_{gem} = 11.2$, $J_{H,P} = J_{5'b,4'} = 5.1$, H-5'b); 3.96 (ddd, 1H, $J_{gem} = 11.2$, $J_{H,P} = 6.0$, $J_{5'a,4'} = 5.1$, H-5'a); 4.17 (dt, 1H, $J_{4',5'} = 5.1$, $J_{4',3'} = 3.6$ H-4'); 4.53 (dt, 1H, $J_{3',2'} = 6.5$, 3.6, $J_{3',4'} = 3.6$, H-3'); 6.26 (dd, 1H, $J_{1',2'} = 7.5$, 6.2, H-1'); 6.96 (m, 2H, H-*m*-C₆H₄OMe); 7.30 (m, 2H, H-*o*-C₆H₄OMe); 8.29 (s, 1H, H-6).

¹³C NMR (125.7 MHz, D₂O): 41.71 (CH₂-2'); 58.20 (CH₃O); 66.44 (d, $J_{C,P} = 4.5$, CH₂-5'); 73.86 (CH-3'); 88.81 (d, $J_{C,P} = 8.1$, CH-4'); 89.03 (CH-1'); 102.29 (C-5); 117.91 (CH-*m*-C₆H₄OMe); 128.00 (C-*i*-C₆H₄OMe); 132.34 (CH-*o*-C₆H₄OMe); 150.94 (CH-6); 159.68 (C-2); 160.98 (C-*p*-C₆H₄OMe); 168.33 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): 3.96.

MS-ESI ($C_{16}H_{19}N_3O_8PS^-$) m/z (% int.) calcd: 444.4 [M]. Found: [M] 444.1 (100).

HRMS-ESI (C₁₆H₁₉N₃O₈PS⁻) *m/z* (% int.) calcd: 444.06359 [M]. Found: 444.06293 [M].

5-[(2-Thienyl)sulfanyl]-2'-deoxycytidine 5'-O-monophosphate (dC^{ThS}MP)

Method A - starting from bis(2-thienyl)disulfide (168.2 mg). Yield: 29 mg (45 %). White solid.

¹H NMR (500.0 MHz, D₂O): 2.31 (dt, 1H, $J_{gem} = 14.0, J_{2'b,1'}$ = 7.0, $J_{2'b,3'} = 6.3$, H-2'b); 2.44 (ddd, 1H, $J_{gem} = 14.0, J_{2'a,1'}$ = 6.2, $J_{2'a,3'} = 3.6$, H-2'a); 4.03 (dd, 2H, $J_{H,P} = 5.6, J_{5',4'} =$

4.5, H-5'); 4.20 (td, 1H, $J_{4',5'} = 4.5$, $J_{4',3'} = 3.6$, H-4'); 4.53 (dt, 1H, $J_{3',2'} = 6.3$, 3.6, $J_{3',4'} = 3.6$, H-3'); 6.21 (dd, 1H, $J_{1',2'} = 7.0$, 6.2, H-1'); 7.01 (dd, 1H, $J_{4,5} = 5.3$, $J_{4,3} = 3.6$, H-4-thienyl); 7.29 (dd, 1H, $J_{3,4} = 3.6$, $J_{3,5} = 1.4$, H-3-thienyl); 7.45 (dd, 1H, $J_{5,4} = 5.3$, $J_{5,3} = 1.4$, H-5-thienyl); 8.32 (s, 1H, H-6).

¹³C NMR (125.7 MHz, D₂O): 42.08 (CH₂-2'); 66.96 (d, $J_{C,P} = 4.7$, CH₂-5'); 73.74 (CH-3'); 88.65 (d, $J_{C,P} = 8.3$, CH-4'); 89.26 (CH-1'); 104.66 (C-5); 130.79 (CH-4-thienyl); 132.68 (CH-5-thienyl); 135.25 (CH-3-thienyl); 135.53 (C-2-thienyl); 150.41 (CH-6); 159.38 (C-2); 167.88 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): 2.72.

MS-ESI (C₁₃H₁₅O₇N₃PS₂⁻) *m/z* (% int.) calcd: 420.4 [M]. Found: 420.1[M] (100).

HRMS-ESI (C₁₃H₁₅O₇N₃PS₂⁻) *m/z* (% int.) calcd: 420.00945 [M]. Found: 420.00928 [M].

5-Phenylselanyl-2'-deoxycytidine 5'-*O*-monophosphate sodium salt (dC^{PhSe}MP)

Method A - starting from (PhSe)₂ (225 mg), Yield: 15.5 mg (21 %). White solid.

¹H NMR (500.0 MHz, D₂O): 2.36 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'b,1'} = 7.5$, $J_{2'b,3'} = 6.5$, H-2'b); 2.44 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.6$, H-2'a); 3.92 (dt, 1H, $J_{gem} = 11.3$,



 NH_2

dC^{ThS}MP

 $J_{5'b,4'} = J_{H,P} = 5.1, H-5'b)$; 3.95 (ddd, 1H, $J_{gem} = 11.3, J_{H,P} = 5.9, J_{5'a,4'} = 5.1, H-5'a)$; 4.17 (td, 1H, $J_{4',5'} = 5.1, J_{4',3'} = 3.6, H-4')$; 4.52 (dt, 1H, $J_{3',2'} = 6.5, 3.6, J_{3',2'} = 3.6, H-3')$; 6.27 (dd, 1H, $J_{1',2'} = 7.5, 6.2, H-1'$); 7.26 – 7.37 (m, 3H, H-*m*,*p*-Ph); 7.41 (m, 2H, H-*o*-Ph); 8.32 (s, 1H, H-6). ¹³C NMR (125.7 MHz, D₂O): 41.67 (CH₂-2'); 66.52 (d, $J_{C,P} = 4.5, CH_2-5'$); 73.85 (CH-3'); 88.73 (d, $J_{C,P} = 8.2, CH-4'$); 88.96 (CH-1'); 97.23 (C-5); 130.03 (CH-*p*-Ph); 132.24 (CH-*o*-Ph); 132.44 (CH-*m*-Ph); 132.57 (C-*i*-Ph); 152.03 (CH-6); 159.91 (C-2); 168.53 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): 4.44.

⁷⁷Se NMR (95.4 MHz, D₂O): 284.52.

MS-ESI (C₁₅H₁₇O₇N₃PSe⁻) *m/z* (% int.) calcd: 462.0 [M]. Found: 462.1 [M] (100).

HRMS-ESI (C₁₅H₁₇O₇N₃PSe⁻) *m/z* (% int.) calcd: 461.99748 [M]. Found: 461.99731 [M].

5-Methylselanyl-2'-deoxycytidine 5'-*O*-monphosphate sodium salt (dC^{MeSe}MP)

Method B: dC^{MeSe} (63 mg, 0.2 mmol), POCl₃ (46 mg, 27.4 μ l, 0.3 mmol, 1.5 equiv.), 90 minutes. Yield: 42 mg (48 %). White solid.

¹H NMR (500.0 MHz, D₂O): 2.18 (s, 3H, CH₃Se); 2.33 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'b,1'} = 7.6$, $J_{2'b,3'} = 6.4$, H-2'b); 2.42 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.4$, H-2'a); 4.01



(dd, 2H, $J_{H,P} = 5.4$, $J_{5',4'} = 4.3$, H-5'); 4.19 (tdd, 1H, $J_{4',5'} = 4.3$, $J_{4',3'} = 3.4$, $J_{H,P} = 1.1$, H-4'); 4.54 (dt, 1H, $J_{3',2'} = 6.4$, 3.4, $J_{3',4'} = 3.4$, H-3'); 6.27 (dd, 1H, $J_{1',2'} = 7.6$, 6.2, H-1'); 8.20 (s, 1H, H-6). ¹³C NMR (125.7 MHz, D₂O): 11.47 (CH₃Se); 41.92 (CH₂-2'); 66.91 (d, $J_{C,P} = 4.7$, CH₂-5'); 73.85 (CH-3'); 88.59 (d, $J_{C,P} = 8.5$, CH-4'); 88.86 (CH-1'); 98.43 (C-5); 150.32 (CH-6); 160.01 (C-2); 168.77 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): 2.09.

⁷⁷Se NMR (95.4 MHz, D₂O): 85.79 (q, $J_{Se,H} = 11.4$).

MS-ESI (C₁₀H₁₅O₇N₃PSe⁻) *m/z* (% int.) calcd: 400.0 [M]. Found: 400.0 [M] (100).

HRMS-ESI (C₁₀H₁₅O₇N₃PSe⁻) *m/z* (% int.) calcd: 399.98183 [M]. Found: 399.98160 [M].

General procedure for copper-mediated sulfanylations or selanylations of dC^ITP (Method A):

To a U-shaped microwave vial sealable with a Teflon cap were added Cu powder (18.5 mg, 0.291 mmol, 1.3 equiv.), 2,2'-bipyridyl (8.8 mg, 0.056 mmol, 0.25 equiv.) and corresponding diselenide or disulfide (0.134 mmol, 0.6 equiv.). The vessel was capped and then evacuated and backfilled with Ar three times. Triethylammonium salt (TEA⁺) of **dC^ITP** (200 mg, 0.223 mmol, 1 equiv.) or a different iodinated dNTP in DMF (2.0 ml, degassed) was injected via a syringe and the vessel was evacuated and backfilled with Ar and the contents were sonicated. The reaction mixture was heated to 80 °C and vigorously stirred for 60 - 70 minutes. The reaction was quenched by slow addition of cold water (5 ml), the precipitate was filtered off and the filtrate evaporated to dryness *in vacuo* at 34-36 °C. The product was purified by reverse phase HPLC [C-18, 0 \rightarrow 50% MeOH in 0.1M aq. TEAB (triethylammonium bicarbonate); solid residue was dissolved in approx. 5 ml H₂O and filtered through two syringe filters prior injection]. Several co-evaporations with water, conversion into a sodium form (Dowex 50WX8 in Na⁺ cycle followed by Chelex 100 resin in Na⁺ cycle^[X3]) followed by freeze-drying from water afforded the product as a white, fluffy powder.

General procedure for sulfanylation of dC^ITP using copper(I) thiophenolate (Method B):

To a U-shaped microwave vial sealable with a Teflon cap were added PhSCu^I (55 mg, 0.318 mmol, 1.1 equiv.) and 2,2'-bipyridyl (98.9 mg, 0.633 mmol, 2.2 equiv.). The vessel was capped, evacuated and backfilled with Ar three times and the solids were dissolved in DMF (2.6 ml, degassed). Triethylammonium salt (TEA⁺) of **dC^ITP** (259 mg, 0.289 mmol, 1 equiv.) or a different iodinated dNTP in DMF (2.6 ml, degassed) was injected via a syringe and the vessel was evacuated and backfilled with Ar and the contents were sonicated. The reaction mixture was heated to 80 °C and vigorously stirred for 60 - 70 minutes. The reaction was quenched by slow addition of cold water (5 ml), the precipitate was filtered off and the filtrate evaporated to dryness *in vacuo* at 34-36 °C. The product was purified by reverse phase HPLC [C-18, 0 \rightarrow 50% MeOH in 0.1M aq. TEAB (triethylammonium bicarbonate); solid residue was dissolved in approx. 5 ml H₂O and filtered through two syringe filters prior injection]. Several co-evaporations with water, conversion into a sodium form (Dowex 50WX8 in Na⁺ cycle followed by Chelex 100 resin in Na⁺ cycle^[S4]) followed by freeze-drying from water afforded the product as a white, fluffy powder.

5-Phenylsulfanyl-2'-deoxycytidine 5'-*O*-triphosphate sodium salt (dC^{PhS}TP)

Method B - starting from PhSCu^I (55 mg, 0.318 mmol, 1.1 equiv.), conditions: 80 °C, 1 hour. Yield: 12 mg (7 %).

¹H NMR (500.0 MHz, D₂O): 2.37 (ddd, 1H, $J_{\text{gem}} = 14.0, J_{2'b,1'} = 7.3, J_{2'b,3'} = 6.3, \text{H-2'b}$;



2.47 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'a,1'} = 6.2$, $J_{2'a,3'} = 3.5$, H-2'a); 4.11 – 4.29 (m, 3H, H-4',5'); 4.62 (dt, 1H, $J_{3',2'} = 6.3$, 3.5, $J_{3',2'} = 3.5$, H-3'); 6.29 (dd, 1H, $J_{1',2'} = 7.3$, 6.2, H-1'); 7.25 – 7.31 (m, 3H, H-o,p-Ph); 7.36 (m, 2H, H-m-Ph); 8.32 (s, 1H, H-6).

¹³C NMR (125.7 MHz, D₂O): 42.07 (CH₂-2'); 68.09 (d, $J_{C,P} = 5.6$, CH₂-5'); 73.44 (CH-3'); 88.36 (d, $J_{C,P} = 8.8$, CH-4'); 89.26 (CH-1'); 100.99 (C-5); 129.42 (CH-*o*-Ph); 129.65 (CH-*p*-Ph); 132.20 (CH-*m*-Ph); 137.26 (C-*i*-Ph); 151.45 (CH-6); 159.71 (C-2); 168.42 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): -22.14 (t, J = 19.7, P_{β}); -10.74 (d, J = 19.7, P_{α}); -9.25 (bd, J = 19.7, P_{γ}).

MS-ESI (C₁₅H₁₈O₁₃N₃NaP₃S⁻) *m/z* (% int.) calcd: 596.3 [M-2H+Na]. Found: 596.0 [M-2H+Na] (25), 494.0 [M-PO₃Na] (100).

HRMS-ESI ($C_{15}H_{18}O_{13}N_3N_3P_3S^-$) m/z (% int.) calcd: 595.96764 [M-2H+Na]. Found: 595.96777 [M-2H+Na].

5-[(2-Thienyl)sulfanyl]-2'-deoxycytidine 5'-O-triphosphate sodium salt (dC^{ThS}TP)

Method A - reaction conditions: 2-thienyl disulfide (30.9 mg), 85 °C, 70 minutes. Yield: 34.5 mg (24 %).

¹H NMR (500.0 MHz, D₂O): 2.34 (dt, 1H, J_{gem} = 14.1, $J_{2'b,1'} = J_{2'b,3'} = 6.7$, H-2'b); 2.44 (ddd,



1H, $J_{\text{gem}} = 14.1$, $J_{2'a,1'} = 6.3$, $J_{2'a,3'} = 3.7$, H-2'a); 4.15 – 4.32 (m, 3H, H-4',5'); 4.63 (dt, 1H, $J_{3',2'} = 6.7$, 3.7, $J_{3',4'} = 3.7$, H-3'); 6.23 (dd, 1H, $J_{1',2'} = 6.7$, 6.3, H-1'); 7.05 (dd, 1H, $J_{4,5} = 5.4$, $J_{4,3} = 3.6$, H-4-thienyl); 7.34 (dd, 1H, $J_{3,4} = 3.6$, $J_{3,5} = 1.3$, H-3-thienyl); 7.49 (dd, 1H, $J_{5,4} = 5.4$, $J_{5,3} = 1.3$, H-5-thienyl); 8.35 (s, 1H, H-6).

¹³C NMR (125.7 MHz, D₂O): 42.06 (CH₂-2'); 67.95 (d, $J_{C,P} = 5.6$, CH₂-5'); 73.17 (CH-3'); 88.46 (d, $J_{C,P} = 8.7$, CH-4'); 89.15 (CH-1'); 104.86 (br, C-5); 130.81 (CH-4-thienyl); 132.74 (CH-5-thienyl); 135.38 (CH-3-thienyl); 135.67 (C-2-thienyl); 150.40 (CH-6); 159.50 (C-2); 167.97 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): -22.26 (t, J = 19.8, P_{β}); -11.35 (d, J = 19.8, P_{α}); -7.59 (bd, J = 19.8, P_{γ}).

MS-ESI ($C_{13}H_{16}O_{13}N_3NaP_3S_2^-$) m/z (% int.) calcd: 601.9 [M-2H+Na]. Found: 601.9 [M-2H+Na] (10), 499.9 [M-PO_3Na] (100).

HRMS-ESI ($C_{13}H_{15}O_{13}N_3Na_2P_3S_2^-$) m/z (% int.) calcd: 601.92406 [M-2H+Na]. Found: 601.92290 [M-2H+Na].

5-Phenylselanyl-2'-deoxycytidine 5'-*O*triphosphate sodium salt (dC^{PhSe}TP)

Method A - starting from (PhSe)₂ (41.9 mg), conditions: 80 °C, 1 hour. Yield: 46.8 mg (30.5 %).



¹H NMR (500.0 MHz, D₂O): 2.37 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'b,1'} = 7.1$, $J_{2'b,3'} = 6.5$, H-2'b); 2.46 (ddd, 1H, $J_{gem} = 14.0$, $J_{2'a,1'} = 6.3$, $J_{2'a,3'} = 3.9$, H-2'a); 4.16 – 4.28 (m, 3H, H-4',5'); 4.63 (dt, 1H, $J_{3',2'} = 6.5$, 3.9, $J_{3',4'} = 3.9$, H-3'); 6.27 (dd, 1H, $J_{1',2'} = 7.1$, 6.3, H-1'); 7.26-7.37 (m, 3H, H-*m*,*p*-Ph); 7.44 (m, 2H, H-*o*-Ph); 8.32 (s, 1H, H-6).

¹³C NMR (125.7 MHz, D₂O): 41.85 (CH₂-2'); 66.98 (d, $J_{C,P} = 5.3$, CH₂-5'); 73.11 (CH-3'); 88.30 (d, $J_{C,P} = 8.4$, CH-4'); 89.06 (CH-1'); 97.52 (C-5); 130.15 (CH-*p*-Ph); 132.43 (CH-*m*-Ph); 132.55 (C-*i*-Ph); 132.69 (CH-*o*-Ph); 151.83 (CH-6); 159.87 (C-2); 168.48 (C-4).

³¹P{¹H} NMR (202.3 MHz, D₂O): -21.25 (t, $J = 19.2, P_{\beta}$); -11.00 (d, $J = 19.2, P_{\alpha}$); -5.52 (d, $J = 19.2, P_{\gamma}$).

⁷⁷Se NMR (95.4 MHz, D₂O): 286.49.

MS-ESI (C₁₅H₁₉O₁₃N₃P₃Se⁻) *m/z* (% int.) calcd: 621.2 [M-H]. Found: 621.9 [M-H] (100).

HRMS-ESI (C₁₅H₁₉O₁₃N₃P₃Se⁻) *m/z* (% int.) calcd: 621.93014 [M-H]. Found: 621.93038 [M-H].

Biochemistry

Table S1: List of ON sequences used in this study

Oligo	Sequence
Primer ^{248-sh}	5'-CATGGGCGGCATGGG-3'
temp ^{oligo1C}	5'-CCCGCCCATGCCGCCCATG-3'
temp ^{Prb4baseII}	5'-CTAGCATGAGCTCAGTCCCATGCCGCCCATG-3'
primer ^{LT25TH}	5'-CAAGGACAAAATACCTGTATTCCTT-3'
primer ^{L20}	5'-GACATCATGAGAGACATCGC-3'
	5'-GACATCATGAGAGACATCGCCTCTGGGCTAATAGGACTACTT
temp ^{FVL-A}	CTAATCTGTAAGAGCAGATCCCTGGACAGGCAAGGAATACAGGT
	ATTTTGTCCTTG-3'

Primer extension - 19-mer template

PEX reactions with $dC^{PhS}TP$, $dC^{PhSe}TP$ or $dC^{ThS}TP$ as substrates were performed in presence of a DNA polymerase (KOD XL, Vent(exo⁻) or Pwo). The reaction mixture (20 µl) contained KOD XL DNA polymerase (0.05 U),Vent (exo⁻) DNA Polymerase (0.16 U) or Pwo polymerase (0.2 U), dGTP (20 µM), either dCTP or $dC^{RX}TP$ (20 µM), 5'-FAM labelled primer^{248-sh} (0.5 µM) and 19-mer template (temp^{oligo1C}, 0.75 µM) in buffer (2 µl) supplied by the manufacturer. Reaction mixtures were incubated for 30 min at 60°C. Before gel loading samples were denatured by addition 20 ul of stop solution (80% [v/v] formamide, 20 mM EDTA, 0.025%, [w/v] bromophenol blue, 0.025 % [w/v] xylene cyanol, MilliQ water) and heated for 5 min at 95°C. Reaction mixtures were separated using 12.5 % denaturing PAGE. Visualization was performed by fluorescence imaging.

Primer extension - 31-mer template

PEX reactions with 31-template (temp^{Prb4baseII}) were performed in the same way as above using KOD XL polymerase (0.25 U), Vent (exo⁻) polymerase (0.2 U) or Pwo polymerase (0.2 U), dGTP, dATP and TTP (200 μ M each), dCTP or **dC^{RX}TP** (200 μ M), 5'-FAM labelled primer (primer^{248-sh}, 0.5 μ M) and 31-mer template (temp^{Prb4baseII}, 0.75 μ M) in buffer (2 μ l) supplied by the manufacturer.

Polymerase chain reaction

PCR reactions with $dC^{PhS}TP$, $dC^{PhSe}TP$ or $dC^{ThS}TP$ as substrates were performed using KOD XL polymerase. The PCR reaction mixture (20 µl) contained KOD XL (0.25 U for positive control and $dC^{ThS}TP$ or 1.75 U for $dC^{PhS}TP$, $dC^{PhSe}TP$), dGTP, dATP and TTP (300 µM each), either dCTP or $dC^{RX}TP$ (300 µM), primers (primer^{LT25TH} and primer^{L20}, 1 µM each) and 98-mer template (temp^{FVL-A}, 0.025 µM) in reaction buffer (2 µl) supplied by the manufacturer. Thirty PCR cycles were run under the following conditions: denaturation for 1 min at 95°C, annealing for 1 min at 53°C, extension for 1 min at 72°C, followed by final extension step of 2 min at 75°C.

a) Reaction mixtures were than separated without purification by use of a 2 % agarose gel with GelRed as an intercalator. Visualization was performed by fluorescence imaging.



Figure S1: PCR experiments using KOD XL DNA polymerase. Lanes 1,7, L: ladder ; lane 2, C⁺: products of PEX with natural dNTPs; lane 3, C⁻: products of PEX with dTTP, dATP, dGTP; lanes 4-6, C^{RX}: products of PCR with dTTP, dATP, dGTP and functionalized **dC^{RX}TP**.

b) Reaction mixtures were purified using QIAquick system according to protocol. In the last step, PCR products were eluted from spin column by either 30 μ l (in the case of C⁺, C⁻, C^{ThS}, C^{PhS}, C^{PhS}) of MilliQ water. The final concentration of prepared modified DNAs was quantified with NanoDrop instrument: 41.1 ng/ μ l (C⁺), 45.2 ng/ μ l (C^{ThS}), 42.0 ng/ μ l (C^{PhS}), 28.3 ng/ μ l (C^{PhSe}). Samples were than separated by use of a 2 % agarose gel with GelRed as an intercalator. Visualization was performed by fluorescence imaging.



Figure S2: PCR experiments using KOD XL DNA polymerase. Lanes 1,7, L: ladder ; lane 2, C⁺: products of PEX with natural dNTPs; lane 3, C⁻: products of PEX with dTTP, dATP, dGTP; lanes 4-6, C^{RX}: products of PCR with dTTP, dATP, dGTP and functionalized **d**C^{RX}**TP**.

Optimization of polymerase chain reaction for dC^{PhSe}TP

PCR reactions with 98-mer template (temp^{FVL-A}) were performed in 20 μ l in the same way as in previous experiment only the additives were added in the reaction mixture or higher concentration of **dC**^{PhSe}**TP** was used. Reaction mixtures were purified again using QIAquick system according to protocol. In the last step, PCR products were eluted from spin column by either 30 μ l (in the case of **C**^{PhSe1}, **C**^{PhSe2}, **C**^{PhSe3}, **C**^{PhSe4}, **C**^{PhSe5}) of MilliQ water. The final concentration of prepared modified DNAs was quantified with NanoDrop instrument.

- a) To the reaction mixture (total volume 20 μl) were added additives: DMSO (100 %, 0.5 μl), formamide (5 %, 0.5 μl), betaine (0.75 M, 0.5 μl), TMAC (tetramethylammonium chloride, 50 mM, 0.5 μl). Concentration of PCR product was 38.6 ng/μl (C^{PhSe1}).
- b) To the reaction mixture (total volume 20 μl) was added additive: MgSO₄ (100 mM, 0.5 μl). Concentration of PCR product was 44.1 ng/μl (C^{PhSe2}).
- c) Concentration of $dC^{PhSe}TP$ in reaction mixture (20 ul) was increased to 450 μ M. Concentration of PCR product was 42.6 ng/ μ l (C^{PhSe3}).

- d) Concentration of $dC^{PhSe}TP$ in reaction mixture (20 ul) was increased to 600 μ M. Concentration of PCR product was 34.5 ng/ μ l (C^{PhSe4}).
- e) Concentration of $dC^{PhSe}TP$ in reaction mixture (20 ul) was increased to 900 μ M. Concentration of PCR product was 36.2 ng/ μ l (C^{PhSe5}).

Samples were than separated by use of a 2 % agarose gel with GelRed as an intercalator. Visualization was performed by fluorescence imaging.





Figure S3: PCR experiments using KOD XL DNA polymerase. Lanes 1,10, L: ladder ; lane 2, C⁺: products of PEX with natural dNTPs; lane 3, C⁻: products of PEX with dTTP, dATP, dGTP; lane 4, C^{PhSe}: products of PCR without additives (dTTP, dATP, dGTP, dC^{PhSe}TP); lane 5, C^{PhSe1}: products of PCR with using additives - DMSO, TMAC, betain, formamide; lane 6, C^{PhSe2}: products of PCR with using MgSO₄ as additive; lane 7, C^{PhSe3}: products of PCR with increasing concentration of dC^{PhSe}TP (1.5x); lane 8, C^{PhSe4}: products of PCR with increasing concentration of dC^{PhSe5}: products of PCR wit

Preparation of ONs for MALDI-TOF Analysis - 31-mer template

The reaction mixture (60 µl) contained primer (primer^{248-sh}, 3.3 µM), a biotinylated or 31-mer template (5'-biotinylated temp^{Prb4baseII}, 3.3 µM), KOD XL DNA polymerase (0.25 U), dGTP, dATP and TTP (220 µM each), and **dC^{RX}TP** (220 µM), in enzymes reaction buffer supplied by the manufacturer (6 µl). The reaction mixture was shaken (300 rmp) for 40 min at 60 °C in a thermal cycler. Streptavidin magnetic particles stock solution (Roche, 60 µL) was washed with binding buffer (3 × 200 µL, 10 mM Tris, 1 mM EDTA, 100 mM NaCl, pH 7.5). The PEX

solution (prepared as described above) and binding buffer (100 µl) were added. Suspension was shaken (1200 rpm) for 30 min at 15 °C. The magnetic beads were collected on a magnet (DynaMag-2, Invitrogen) and washed with wash buffer ($3 \times 200 \mu$ l, 10 mM Tris, 1 mM EDTA, 500 mM NaCl, pH 7.5) and water ($5 \times 200 \mu$ l). Then water (50μ L) was added and the sample was denatured for 2 min at 55 °C and 900 rpm. The beads were collected on a magnet and the solution was transferred into a clean vial. The product was evaporated to dryness, then dissolved in the mixture of water/acetonitrile (1:1, 5 ul) and analyzed by MALDI-TOF mass spectrometry.

Copies of NMR spectra

5-Phenylsulfanyl-2'-deoxycytidine





S29



5-[(4-Methoxyphenyl)sulfanyl]-2'-deoxycytidine



5-[(2,4-Dinitrophenyl)sulfanyl]-2'-deoxycytidine

5-[(2-Thienyl)sulfanyl]-2'-deoxycytidine



5-Phenylselanyl-2'-deoxycytidine





5-Methylselanyl-2'-deoxycytidine





5-Phenylsulfanyl-2'-deoxyuridine



5-[(2-Thienyl)sulfanyl]-2'-deoxyuridine



5-Phenylselanyl-2'-deoxyuridine

5-Methylselanyl-2'-deoxyuridine

7-Phenylsulfanyl-7-deaza-2'-deoxyadenosine

7-Phenylselanyl-7-deaza-2'-deoxyadenosine

BOTHA FBH-127 77Se NMR in DMSO-d6 14-03-16 RA

7-Methylselanyl-7-deaza-2'-deoxyadenosine

7-Phenylsulfanyl-7-deaza-2'-deoxyguanosine

7-Phenylselanyl-7-deaza-2'-deoxyguanosine

S49

5-Phenylsulfanyl-2'-deoxycytidine 5'-O-monophosphate sodium salt

5-[(4-Nitrophenyl)sulfanyl]-2'-deoxycytidine 5'-O-monophosphate sodium salt

5-[(4-Methoxyphenyl)sulfanyl]-2'-deoxycytidine 5'-*O*-monophosphate sodium

salt

5-[(2-Thienyl)sulfanyl]-2'-deoxycytidine 5'-O-monophosphate

5-Phenylselanyl-2'-deoxycytidine 5'-*O*-monophosphate sodium salt

o

-20

77Se (ppm)

5-Phenylsulfanyl-2'-deoxycytidine 5'-O-triphosphate sodium salt

5-Phenylselanyl-2'-deoxycytidine 5'-O-triphosphate sodium salt

5-[(2-Thienyl)sulfanyl]-2'-deoxycytidine 5'-O-triphosphate sodium salt

MALDI-TOF experiments of PEX products for Prb4Basell

Figure S4: MALDI spectrum of **ON**^{4ThS} (**dC**^{ThS}**TP**). M (calc.) = 10073.2; M (found) = 10075.1 [M+2H]⁺, 9948.2 [M-T]⁺

Figure S5: MALDI spectrum of **ON**^{4PhS} (**dC**^{PhS}**TP**). M (calc.) = 10049.3; M (found) = 10050.8 [M+H]⁺, 9924.0 [M-T]⁺

Figure S6: MALDI spectrum of **ON**^{4PhSe} (**dC**^{PhSe}**TP**). M (calc.) = 10241.1; M (found) = 10240.2 [M]⁺, 10113.3 [M-T]⁺, 9856.6 [template]⁺

References

S1. Bergstrom, D. E.; Beal, P.; Jenson, J.; Lin X.: J. Org. Chem., 1991, 56, 5598-5602.

S2. Schinazi, R. F.; Arbiser, J.; Lee, J. J. S.; Kalman, T. I.; Prusoff W. H.: *J. Med. Chem.*, **1986**, *29*, 1293-1295.

S3. Hassan, A. E. A.; Sheng, J.; Jiang, J.; Zhang, W.; Huang, Z.: Org. Lett., **2009**, *11*, 2503-2506.

S4. Sontheimer, G. M.; Kalbitzer, H. R.; Hasselbach, W.: Biochem. 1987, 26, 2706-2711.